HR Execs on the Move

VenatoRx

www.venatorx.com

 
VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel anti-infective agents to address the threat of antibiotic resistance. The company name, VenatoRx (ven-a-TOR-ex), derives from the latin word “venator”, meaning hunter and “Rx”, the medical symbol for drugs. The pursuit, or “hunt”, for new drugs is the core mission of the company. Located northwest of Philadelphia in Malvern, PA, the company was founded in 2010 by Drs. Burns, Xerri, and Pevear. Since founding, the company has received multiple awards from the NIH, including 5 Small Business Innovative Research (SBIR) grants and an R01 grant. The company ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.venatorx.com
  • 30 Spring Mill Drive
    Malvern, PA USA 19355
  • Phone: 610.644.8935

Executives

Name Title Contact Details
Christina Amendola
Director of Human Profile
Jennifer Nelson
Vice President, R&D Program Management Profile
Hongzi Chen
Senor Director Biometrics, Research and Development Profile
Larry Rosen
Vice President Pharmaceutical Product Development Profile

Similar Companies

Indevus Pharmaceuticals

Indevus Pharmaceuticals Inc. is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Agrinos

Agrinos is a biological crop input provider committed to improving the productivity and sustainability of modern agriculture worldwide. Our products help farmers by providing increased crop yield and productivity, improved crop quality, enhanced efficiency of conventional fertilizer and a reduced environmental footprint.

Protagonist Therapeutics

Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to ‘injectable drugs’. Protagonist’s technology platform is aimed at overcoming these restrictions and expanding the scope of peptide therapeutics to address unmet needs. Specific emphasis is placed on identifying ‘orally stable’ scaffolds and/or engineering oral stability characteristics onto them. The platform has been optimized over the years and involves synergistic integration of rational drug design, diversity oriented computational tools, phage display libraries, recombinant peptide expression, ex vivo oral stability methods, and peptide/medicinal chemistry techniques. This activity has led to the identification of ‘privileged scaffolds’ with favorable oral stability characteristics. Furthermore, the technology platform is well suited both for de novo discovery against a target and optimization around a given chemical starting point.

HudsonAlpha Institute for Biotechnology

HudsonAlpha Institute seeks to expand the science of human genomics and hasten its movement into the marketplace where discoveries can benefit society.

Takeda San Francisco

Takeda San Francisco is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.